Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma

J Clin Oncol. 2012 Feb 20;30(6):e76-8. doi: 10.1200/JCO.2011.38.7886. Epub 2011 Dec 27.

Authors

Michela Maur¹, Chiara Tomasello, Antonio Frassoldati, Maria Vittoria Dieci, Elena Barbieri, Pierfranco Conte

Affiliation

¹ Department of Oncology, Hematology, and Respiratory Diseases, University of Modena and Reggio Emilia Hospital, via del Pozzo 71, 41124 Modena, Italy.

PMID: 22203769
DOI: 10.1200/JCO.2011.38.7886

No abstract available

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents / adverse effects
Female
Humans
Ipilimumab
Melanoma / drug therapy*
Middle Aged
Posterior Leukoencephalopathy Syndrome / chemically induced*
Posterior Leukoencephalopathy Syndrome / diagnosis
Skin Neoplasms / drug therapy*
Vaginal Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Ipilimumab